CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
OmniSpirant is developing a gene therapy using stem cell exosomes for treating cystic fibrosis. The therapy aims to improve lung function and patient quality of life by enhancing mucus penetration and gene delivery.
Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucuspenetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTRgene expression and function) and also be applicable to 100% of the CF global population.
This approach, using a combinedpatent pending exosome surface engineering for enhanced mucus penetration and cell transfection with a tailored vibratingmesh nebulisation aerosol deli…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
